Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
Nils JedickeMetodi V StankovAnne CossmannAlexandra Dopfer-JablonkaChristine KnuthGerrit AhrenstorfGema Morillas RamosGeorg Martin Norbert BehrensPublished in: HIV medicine (2021)
The majority of PLWH mounted robust responses after complete BNT162b2 vaccination but overall amounts of antibodies directed against the SARS-CoV-2 receptor-binding domain were variable. The impact on clinical efficacy remains unclear.
Keyphrases
- immune response
- sars cov
- antiretroviral therapy
- hiv infected
- human immunodeficiency virus
- hiv aids
- hiv infected patients
- hiv positive
- dendritic cells
- toll like receptor
- respiratory syndrome coronavirus
- binding protein
- transcription factor
- hepatitis c virus
- inflammatory response
- south africa
- men who have sex with men